Systemic lupus erythematosus and pregnancy

Area of Science:

• Rheumatology
• Obstetrics
• Immunology

Background:

• Systemic lupus erythematosus (SLE) presents variable effects during pregnancy, including improvement, exacerbation, or no change.
• Disease activity at conception is a critical determinant of pregnancy outcomes in SLE patients.
• Quiescent SLE generally leads to favorable pregnancy outcomes, whereas active, uncontrolled disease is associated with high abortion rates.

Purpose of the Study:

• To investigate the impact of systemic lupus erythematosus (SLE) activity during pregnancy on pregnancy outcomes.
• To identify specific autoantibodies associated with adverse pregnancy outcomes in SLE patients.
• To understand the risks of neonatal lupus and its manifestations in infants born to mothers with SLE.

Main Methods:

• Review of SLE patient data during pregnancy.
• Analysis of correlations between SLE disease activity at conception and pregnancy outcomes.
• Identification and assessment of specific autoantibodies (e.g., antiphospholipid antibodies, anti-Ro/SSA, anti-La/SSB) and their association with abortion and neonatal lupus.

Main Results:

• SLE activity at conception significantly influences pregnancy outcomes.
• High abortion rates are observed in SLE patients with active, uncontrollable disease.
• Specific autoantibodies, including IgG antiphospholipid antibodies, anti-Ro/SSA, and anti-La/SSB, are linked to increased risks of abortion and neonatal lupus complications.

Conclusions:

• Pregnancy management in SLE requires careful assessment of disease activity at conception.
• Monitoring for specific autoantibodies is crucial for predicting and managing pregnancy complications in SLE.
• Neonatal lupus, characterized by dermatitis, heart block, and thrombocytopenia, is a significant risk associated with certain maternal autoantibodies.